145 related articles for article (PubMed ID: 22833925)
1. Delivery of antigens by viral vectors for vaccination.
Krause A; Worgall S
Ther Deliv; 2011 Jan; 2(1):51-70. PubMed ID: 22833925
[TBL] [Abstract][Full Text] [Related]
2. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
3. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
5. New insights on adenovirus as vaccine vectors.
Lasaro MO; Ertl HC
Mol Ther; 2009 Aug; 17(8):1333-9. PubMed ID: 19513019
[TBL] [Abstract][Full Text] [Related]
6. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.
Seregin SS; Amalfitano A
Expert Opin Biol Ther; 2009 Dec; 9(12):1521-31. PubMed ID: 19780714
[TBL] [Abstract][Full Text] [Related]
7. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.
Matthews QL
Mol Pharm; 2011 Feb; 8(1):3-11. PubMed ID: 21047139
[TBL] [Abstract][Full Text] [Related]
8. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.
Matthews QL; Yang P; Wu Q; Belousova N; Rivera AA; Stoff-Khalili MA; Waehler R; Hsu HC; Li Z; Li J; Mountz JD; Wu H; Curiel DT
Virol J; 2008 Aug; 5():98. PubMed ID: 18718011
[TBL] [Abstract][Full Text] [Related]
9. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.
De BP; Pagovich OE; Hicks MJ; Rosenberg JB; Moreno AY; Janda KD; Koob GF; Worgall S; Kaminsky SM; Sondhi D; Crystal RG
Hum Gene Ther; 2013 Jan; 24(1):58-66. PubMed ID: 23140508
[TBL] [Abstract][Full Text] [Related]
10. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
11. Viral Vector-Based Gene Therapy.
Li X; Le Y; Zhang Z; Nian X; Liu B; Yang X
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175441
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
[TBL] [Abstract][Full Text] [Related]
13. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors.
Kreppel F; Hagedorn C
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670859
[TBL] [Abstract][Full Text] [Related]
14. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
Hashimoto M; Boyer JL; Hackett NR; Wilson JM; Crystal RG
Infect Immun; 2005 Oct; 73(10):6885-91. PubMed ID: 16177368
[TBL] [Abstract][Full Text] [Related]
15. Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions.
Weklak D; Pembaur D; Koukou G; Jönsson F; Hagedorn C; Kreppel F
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372506
[TBL] [Abstract][Full Text] [Related]
16. Adenoviruses as vaccine vectors.
Tatsis N; Ertl HC
Mol Ther; 2004 Oct; 10(4):616-29. PubMed ID: 15451446
[TBL] [Abstract][Full Text] [Related]
17. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.
Ophorst OJ; Kostense S; Goudsmit J; De Swart RL; Verhaagh S; Zakhartchouk A; Van Meijer M; Sprangers M; Van Amerongen G; Yüksel S; Osterhaus AD; Havenga MJ
Vaccine; 2004 Aug; 22(23-24):3035-44. PubMed ID: 15297053
[TBL] [Abstract][Full Text] [Related]
18. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.
Wortmann A; Vöhringer S; Engler T; Corjon S; Schirmbeck R; Reimann J; Kochanek S; Kreppel F
Mol Ther; 2008 Jan; 16(1):154-62. PubMed ID: 17848961
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.
Gu L; Krendelchtchikova V; Krendelchtchikov A; Farrow AL; Derdeyn CA; Matthews QL
Virology; 2016 Jan; 487():75-84. PubMed ID: 26499044
[TBL] [Abstract][Full Text] [Related]
20. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
Kelly MJ; O'Keeffe GW; Sullivan AM
Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
